[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f_sp-K6-xgY65fSCOx0KZlXxHNUHUJR4VJfYtsRexqlQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"Tan Tock Seng Hospital",[4],102,false,27,7,51044,2,84,[14,16,19,22,24,26,28,30],{"name":15,"count":8},"Stroke",{"name":17,"count":18},"Knee Osteoarthritis",5,{"name":20,"count":21},"Traumatic Brain Injury",3,{"name":23,"count":21},"Acquired Brain Injury",{"name":25,"count":11},"Fatigue",{"name":27,"count":11},"Age-Related Macular Degeneration",{"name":29,"count":11},"Wet Age-related Macular Degeneration",{"name":31,"count":11},"COVID-19",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT05199324","Early Oral Switch for Uncomplicated Gram-negative Bacteraemia","2026-05","Oral fluoroquinolones (most commonly, ciprofloxacin) or oral trimethoprim-sulfamethoxazole",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,72,90,130,157,184,212,230,248,266,292,310,328,346,373,399,429,447,472,499,517,545,563,581,606,630,656,674,707,733],{"intervention":37,"totalTrials":47,"cells":48},1,{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":58,"NA":70},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":51},[],{"trials":59,"activeCount":47,"soonestReadout":36},[60],{"nctId":34,"briefTitle":35,"status":61,"phases":62,"primaryCompletion":36,"completion":63,"start":64,"enrollment":65,"conditions":66,"interventions":68},"RECRUITING",[43],"2026-07","2022-06-03",720,[67],"Gram-negative Bacteraemia",[37,69],"Standard of care intravenous antibiotics",{"trials":71,"activeCount":51},[],{"intervention":69,"totalTrials":47,"cells":73},{"EARLY_PHASE1":74,"PHASE1":76,"PHASE2":78,"PHASE3":80,"PHASE4":82,"NA":88},{"trials":75,"activeCount":51},[],{"trials":77,"activeCount":51},[],{"trials":79,"activeCount":51},[],{"trials":81,"activeCount":51},[],{"trials":83,"activeCount":47,"soonestReadout":36},[84],{"nctId":34,"briefTitle":35,"status":61,"phases":85,"primaryCompletion":36,"completion":63,"start":64,"enrollment":65,"conditions":86,"interventions":87},[43],[67],[37,69],{"trials":89,"activeCount":51},[],{"intervention":91,"totalTrials":11,"cells":92},"Dapagliflozin",{"EARLY_PHASE1":93,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":113,"NA":128},{"trials":94,"activeCount":51},[],{"trials":96,"activeCount":51},[],{"trials":98,"activeCount":51},[],{"trials":100,"activeCount":51},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":107,"start":108,"enrollment":51,"conditions":109,"interventions":112},"NCT04764097","Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease","WITHDRAWN",[41,42],"2025-06","2026-06","2021-06",[110,111],"Cardiovascular Diseases","End Stage Renal Disease",[91],{"trials":114,"activeCount":51},[115],{"nctId":116,"briefTitle":117,"status":118,"phases":119,"primaryCompletion":120,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":125},"NCT05440591","Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes","UNKNOWN",[43],"2023-05-10","2019-04-01",150,[124],"Diabetes",[91,126,127],"MetFORMIN 500 Mg Oral","Dapagliflozin \u002F metFORMIN Pill",{"trials":129,"activeCount":51},[],{"intervention":131,"totalTrials":47,"cells":132},"Vitamin D supplementation",{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":141,"NA":155},{"trials":134,"activeCount":51},[],{"trials":136,"activeCount":51},[],{"trials":138,"activeCount":51},[],{"trials":140,"activeCount":51},[],{"trials":142,"activeCount":51},[143],{"nctId":144,"briefTitle":145,"status":146,"phases":147,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":154},"NCT01741181","Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2","COMPLETED",[43],"2014-11","2012-09",64,[152,153],"Diabetes Mellitus Type 2","Vitamin D Deficiency",[131],{"trials":156,"activeCount":51},[],{"intervention":158,"totalTrials":47,"cells":159},"Tetanus-diphtheria-pertussis vaccine",{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":182},{"trials":161,"activeCount":51},[],{"trials":163,"activeCount":51},[],{"trials":165,"activeCount":51},[],{"trials":167,"activeCount":51},[],{"trials":169,"activeCount":51},[170],{"nctId":171,"briefTitle":172,"status":146,"phases":173,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":180},"NCT02655874","Tropical Influenza Control Strategies for the Elderly",[43],"2017-06","2017-10","2016-05",200,[179],"Influenza, Human",[181,181,158],"Influenza vaccine",{"trials":183,"activeCount":51},[],{"intervention":185,"totalTrials":47,"cells":186},"Homologous mRNA booster vaccine",{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":210},{"trials":188,"activeCount":51},[],{"trials":190,"activeCount":51},[],{"trials":192,"activeCount":51},[],{"trials":194,"activeCount":51},[],{"trials":196,"activeCount":51},[197],{"nctId":198,"briefTitle":199,"status":146,"phases":200,"primaryCompletion":201,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":206},"NCT05142319","Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]",[43],"2023-06-01","2024-05-07","2021-10-12",326,[31],[185,207,208,209],"Heterologous mRNA booster vaccine","COVAXIN","Nuvaxovid",{"trials":211,"activeCount":51},[],{"intervention":207,"totalTrials":47,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":228},{"trials":215,"activeCount":51},[],{"trials":217,"activeCount":51},[],{"trials":219,"activeCount":51},[],{"trials":221,"activeCount":51},[],{"trials":223,"activeCount":51},[224],{"nctId":198,"briefTitle":199,"status":146,"phases":225,"primaryCompletion":201,"completion":202,"start":203,"enrollment":204,"conditions":226,"interventions":227},[43],[31],[185,207,208,209],{"trials":229,"activeCount":51},[],{"intervention":208,"totalTrials":47,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":246},{"trials":233,"activeCount":51},[],{"trials":235,"activeCount":51},[],{"trials":237,"activeCount":51},[],{"trials":239,"activeCount":51},[],{"trials":241,"activeCount":51},[242],{"nctId":198,"briefTitle":199,"status":146,"phases":243,"primaryCompletion":201,"completion":202,"start":203,"enrollment":204,"conditions":244,"interventions":245},[43],[31],[185,207,208,209],{"trials":247,"activeCount":51},[],{"intervention":209,"totalTrials":47,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":258,"NA":264},{"trials":251,"activeCount":51},[],{"trials":253,"activeCount":51},[],{"trials":255,"activeCount":51},[],{"trials":257,"activeCount":51},[],{"trials":259,"activeCount":51},[260],{"nctId":198,"briefTitle":199,"status":146,"phases":261,"primaryCompletion":201,"completion":202,"start":203,"enrollment":204,"conditions":262,"interventions":263},[43],[31],[185,207,208,209],{"trials":265,"activeCount":51},[],{"intervention":267,"totalTrials":47,"cells":268},"Oxycodone",{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":277,"NA":290},{"trials":270,"activeCount":51},[],{"trials":272,"activeCount":51},[],{"trials":274,"activeCount":51},[],{"trials":276,"activeCount":51},[],{"trials":278,"activeCount":51},[279],{"nctId":280,"briefTitle":281,"status":146,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":288},"NCT01672112","Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain",[43],"2015-01","2012-07",40,[287],"Postcraniotomy Pain",[267,289],"Codeine",{"trials":291,"activeCount":51},[],{"intervention":289,"totalTrials":47,"cells":293},{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":308},{"trials":295,"activeCount":51},[],{"trials":297,"activeCount":51},[],{"trials":299,"activeCount":51},[],{"trials":301,"activeCount":51},[],{"trials":303,"activeCount":51},[304],{"nctId":280,"briefTitle":281,"status":146,"phases":305,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":306,"interventions":307},[43],[287],[267,289],{"trials":309,"activeCount":51},[],{"intervention":126,"totalTrials":47,"cells":311},{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":318,"PHASE4":320,"NA":326},{"trials":313,"activeCount":51},[],{"trials":315,"activeCount":51},[],{"trials":317,"activeCount":51},[],{"trials":319,"activeCount":51},[],{"trials":321,"activeCount":51},[322],{"nctId":116,"briefTitle":117,"status":118,"phases":323,"primaryCompletion":120,"completion":120,"start":121,"enrollment":122,"conditions":324,"interventions":325},[43],[124],[91,126,127],{"trials":327,"activeCount":51},[],{"intervention":127,"totalTrials":47,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":344},{"trials":331,"activeCount":51},[],{"trials":333,"activeCount":51},[],{"trials":335,"activeCount":51},[],{"trials":337,"activeCount":51},[],{"trials":339,"activeCount":51},[340],{"nctId":116,"briefTitle":117,"status":118,"phases":341,"primaryCompletion":120,"completion":120,"start":121,"enrollment":122,"conditions":342,"interventions":343},[43],[124],[91,126,127],{"trials":345,"activeCount":51},[],{"intervention":347,"totalTrials":47,"cells":348},"Botulinum toxin type A",{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":369,"NA":371},{"trials":350,"activeCount":51},[],{"trials":352,"activeCount":51},[],{"trials":354,"activeCount":51},[],{"trials":356,"activeCount":51},[357],{"nctId":358,"briefTitle":359,"status":118,"phases":360,"primaryCompletion":361,"completion":362,"start":363,"enrollment":364,"conditions":365,"interventions":368},"NCT04274608","Intra-gastric Fundal and Body Injection of Botulinum Toxin A for Weight Loss, a Randomized Controlled Trial",[41,42],"2021-07","2022-07","2020-01-01",18,[366,367],"Obesity","Weight Loss",[347],{"trials":370,"activeCount":51},[],{"trials":372,"activeCount":51},[],{"intervention":374,"totalTrials":47,"cells":375},"Hydroxychloroquine Sulfate 200 milligram (mg) Tab",{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":395,"NA":397},{"trials":377,"activeCount":51},[],{"trials":379,"activeCount":51},[],{"trials":381,"activeCount":51},[],{"trials":383,"activeCount":51},[384],{"nctId":385,"briefTitle":386,"status":104,"phases":387,"primaryCompletion":388,"completion":389,"start":390,"enrollment":51,"conditions":391,"interventions":394},"NCT04342156","Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19",[42],"2020-08","2020-10","2020-04",[392,393],"Coronavirus Infection","Hydroxychloroquine Adverse Reaction",[374],{"trials":396,"activeCount":51},[],{"trials":398,"activeCount":51},[],{"intervention":400,"totalTrials":47,"cells":401},"Haldol 2mg\u002Fml oral solution",{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":425,"NA":427},{"trials":403,"activeCount":51},[],{"trials":405,"activeCount":51},[],{"trials":407,"activeCount":51},[],{"trials":409,"activeCount":51},[410],{"nctId":411,"briefTitle":412,"status":118,"phases":413,"primaryCompletion":414,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":423},"NCT04833023","HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial",[42],"2024-12","2022-05-18",72,[418,419,420,421,422],"Haloperidol","Advanced Cancer","Hyperactive Delirium","Olanzapine","End-stage Organ Disease",[400,424],"Olanzapine Actavis 5mg orodispersible",{"trials":426,"activeCount":51},[],{"trials":428,"activeCount":51},[],{"intervention":424,"totalTrials":47,"cells":430},{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":437,"PHASE4":443,"NA":445},{"trials":432,"activeCount":51},[],{"trials":434,"activeCount":51},[],{"trials":436,"activeCount":51},[],{"trials":438,"activeCount":51},[439],{"nctId":411,"briefTitle":412,"status":118,"phases":440,"primaryCompletion":414,"completion":414,"start":415,"enrollment":416,"conditions":441,"interventions":442},[42],[418,419,420,421,422],[400,424],{"trials":444,"activeCount":51},[],{"trials":446,"activeCount":51},[],{"intervention":448,"totalTrials":47,"cells":449},"Oral capsule faecal microbiota transplantation",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":468,"NA":470},{"trials":451,"activeCount":51},[],{"trials":453,"activeCount":51},[],{"trials":455,"activeCount":51},[],{"trials":457,"activeCount":51},[458],{"nctId":459,"briefTitle":460,"status":118,"phases":461,"primaryCompletion":462,"completion":463,"start":361,"enrollment":464,"conditions":465,"interventions":467},"NCT04746222","Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization",[41,42],"2022-10","2023-07",108,[466],"Carbapenem-Resistant Enterobacteriaceae Infection",[448],{"trials":469,"activeCount":51},[],{"trials":471,"activeCount":51},[],{"intervention":473,"totalTrials":47,"cells":474},"Polymyxin B",{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":495,"NA":497},{"trials":476,"activeCount":51},[],{"trials":478,"activeCount":51},[],{"trials":480,"activeCount":51},[],{"trials":482,"activeCount":51},[483],{"nctId":484,"briefTitle":485,"status":104,"phases":486,"primaryCompletion":487,"completion":488,"start":283,"enrollment":51,"conditions":489,"interventions":493},"NCT02134106","Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria",[41,42],"2015-10","2015-12",[490,491,492],"Bacteremia","Healthcare-associated Pneumonia","Ventilator-associated Pneumonia",[473,494],"Polymyxin B + Doripenem",{"trials":496,"activeCount":51},[],{"trials":498,"activeCount":51},[],{"intervention":494,"totalTrials":47,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":513,"NA":515},{"trials":502,"activeCount":51},[],{"trials":504,"activeCount":51},[],{"trials":506,"activeCount":51},[],{"trials":508,"activeCount":51},[509],{"nctId":484,"briefTitle":485,"status":104,"phases":510,"primaryCompletion":487,"completion":488,"start":283,"enrollment":51,"conditions":511,"interventions":512},[41,42],[490,491,492],[473,494],{"trials":514,"activeCount":51},[],{"trials":516,"activeCount":51},[],{"intervention":518,"totalTrials":47,"cells":519},"Flublok Quadrivalent vaccine",{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":526,"PHASE4":541,"NA":543},{"trials":521,"activeCount":51},[],{"trials":523,"activeCount":51},[],{"trials":525,"activeCount":51},[],{"trials":527,"activeCount":51},[528],{"nctId":529,"briefTitle":530,"status":146,"phases":531,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":538},"NCT05479370","Immunogenicity Trial of 3 Influenza Vaccines",[42],"2023-04-14","2024-02-06","2022-09-29",366,[537],"Influenza Vaccination",[518,539,540],"Fluarix Quadrivalent vaccine","Flucelvax Quadrivalent vaccine",{"trials":542,"activeCount":51},[],{"trials":544,"activeCount":51},[],{"intervention":539,"totalTrials":47,"cells":546},{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":559,"NA":561},{"trials":548,"activeCount":51},[],{"trials":550,"activeCount":51},[],{"trials":552,"activeCount":51},[],{"trials":554,"activeCount":51},[555],{"nctId":529,"briefTitle":530,"status":146,"phases":556,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":557,"interventions":558},[42],[537],[518,539,540],{"trials":560,"activeCount":51},[],{"trials":562,"activeCount":51},[],{"intervention":540,"totalTrials":47,"cells":564},{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":571,"PHASE4":577,"NA":579},{"trials":566,"activeCount":51},[],{"trials":568,"activeCount":51},[],{"trials":570,"activeCount":51},[],{"trials":572,"activeCount":51},[573],{"nctId":529,"briefTitle":530,"status":146,"phases":574,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":575,"interventions":576},[42],[537],[518,539,540],{"trials":578,"activeCount":51},[],{"trials":580,"activeCount":51},[],{"intervention":582,"totalTrials":47,"cells":583},"Eribulin Mesylate",{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":585,"activeCount":51},[],{"trials":587,"activeCount":51},[],{"trials":589,"activeCount":51},[590],{"nctId":591,"briefTitle":592,"status":118,"phases":593,"primaryCompletion":594,"completion":594,"start":595,"enrollment":596,"conditions":597,"interventions":599},"NCT03412955","A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes",[41],"2020-04-30","2017-03-08",14,[598],"Breast Cancer",[582],{"trials":601,"activeCount":51},[],{"trials":603,"activeCount":51},[],{"trials":605,"activeCount":51},[],{"intervention":607,"totalTrials":47,"cells":608},"Gefetinib",{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":624,"PHASE4":626,"NA":628},{"trials":610,"activeCount":51},[],{"trials":612,"activeCount":51},[],{"trials":614,"activeCount":51},[615],{"nctId":616,"briefTitle":617,"status":118,"phases":618,"primaryCompletion":619,"completion":619,"start":620,"enrollment":285,"conditions":621,"interventions":623},"NCT00282100","Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma",[41],"2019-09","2005-12",[622],"Liver Cancer",[607],{"trials":625,"activeCount":51},[],{"trials":627,"activeCount":51},[],{"trials":629,"activeCount":51},[],{"intervention":631,"totalTrials":47,"cells":632},"Safety of intracameral levofloxacin in cataract surgery",{"EARLY_PHASE1":633,"PHASE1":646,"PHASE2":648,"PHASE3":650,"PHASE4":652,"NA":654},{"trials":634,"activeCount":51},[635],{"nctId":636,"briefTitle":637,"status":146,"phases":638,"primaryCompletion":639,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":644},"NCT06710977","To Compare the Safety and Efficacy of Intracameral Levofloxacin and Intracameral Cefazolin in Reducing Rates of Endophthalmitis Following Cataract Surgery.",[39],"2024-09-01","2022-01-01",50,[643],"Cataract",[631,645],"Use of intracameral cefazolin in cataract surgery",{"trials":647,"activeCount":51},[],{"trials":649,"activeCount":51},[],{"trials":651,"activeCount":51},[],{"trials":653,"activeCount":51},[],{"trials":655,"activeCount":51},[],{"intervention":645,"totalTrials":47,"cells":657},{"EARLY_PHASE1":658,"PHASE1":664,"PHASE2":666,"PHASE3":668,"PHASE4":670,"NA":672},{"trials":659,"activeCount":51},[660],{"nctId":636,"briefTitle":637,"status":146,"phases":661,"primaryCompletion":639,"completion":639,"start":640,"enrollment":641,"conditions":662,"interventions":663},[39],[643],[631,645],{"trials":665,"activeCount":51},[],{"trials":667,"activeCount":51},[],{"trials":669,"activeCount":51},[],{"trials":671,"activeCount":51},[],{"trials":673,"activeCount":51},[],{"intervention":675,"totalTrials":11,"cells":676},"Influenza Vaccine",{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":683,"PHASE4":685,"NA":691},{"trials":678,"activeCount":51},[],{"trials":680,"activeCount":51},[],{"trials":682,"activeCount":51},[],{"trials":684,"activeCount":51},[],{"trials":686,"activeCount":51},[687],{"nctId":171,"briefTitle":172,"status":146,"phases":688,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":689,"interventions":690},[43],[179],[181,181,158],{"trials":692,"activeCount":51},[693],{"nctId":694,"briefTitle":695,"status":118,"phases":696,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":706},"NCT03399357","Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial",[],"2018-12-31","2019-02-28","2017-05-31",240,[675,702,703,153,704,705],"Immune Response","Elderly","Metabolic Disease","Diabetes Mellitus",[675],{"intervention":708,"totalTrials":47,"cells":709},"Glycerine Magnesium sulphate paste",{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":716,"PHASE4":718,"NA":720},{"trials":711,"activeCount":51},[],{"trials":713,"activeCount":51},[],{"trials":715,"activeCount":51},[],{"trials":717,"activeCount":51},[],{"trials":719,"activeCount":51},[],{"trials":721,"activeCount":51},[722],{"nctId":723,"briefTitle":724,"status":146,"phases":725,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":731},"NCT01226069","Effectiveness of Topical Glycerine Sulphate Paste, Hirudoid Cream and Nil Application on Superficial Phlebitis",[44],"2010-02","2009-11",147,[730],"Infection",[708,732],"Mucopolysaccharide polysulphate",{"intervention":732,"totalTrials":47,"cells":734},{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":741,"PHASE4":743,"NA":745},{"trials":736,"activeCount":51},[],{"trials":738,"activeCount":51},[],{"trials":740,"activeCount":51},[],{"trials":742,"activeCount":51},[],{"trials":744,"activeCount":51},[],{"trials":746,"activeCount":51},[747],{"nctId":723,"briefTitle":724,"status":146,"phases":748,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":749,"interventions":750},[44],[730],[708,732]]